Detalhe da pesquisa
1.
REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer.
Future Oncol
; 15(30): 3427-3433, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31509028
2.
RRx-001, A novel dinitroazetidine radiosensitizer.
Invest New Drugs
; 34(3): 371-7, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26841903
3.
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.
Lancet Oncol
; 16(9): 1133-1142, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26296952
4.
A Review of Persistent Post-COVID Syndrome (PPCS).
Clin Rev Allergy Immunol
; 64(1): 66-74, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33609255
5.
Toxicology and biodistribution of AdAPT-001, a replication-competent type 5 adenovirus with a trap for the immunosuppressive cytokine, TGF-beta.
Am J Cancer Res
; 11(10): 5184-5189, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34765319
6.
RRx-001, a downregulator of the CD47- SIRPα checkpoint pathway, does not cause anemia or thrombocytopenia.
Expert Opin Drug Metab Toxicol
; 17(4): 355-357, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33432831
7.
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
J Med Chem
; 64(11): 7261-7271, 2021 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34043360
8.
A Review of Newly Diagnosed Glioblastoma.
Front Oncol
; 10: 574012, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33614476
9.
RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic".
Oncoimmunology
; 9(1): 1746172, 2020 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33457091
10.
Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19.
Semin Oncol
; 47(5): 305-308, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32718560
11.
TGF-beta: a master immune regulator.
Expert Opin Ther Targets
; 24(5): 427-438, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32228232
12.
COVID-19 and cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making.
Biochim Biophys Acta Rev Cancer
; 1874(2): 188412, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32827582
13.
Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review.
Neoplasia
; 20(1): 92-98, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29227909
14.
Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells.
Oncotarget
; 9(34): 23439-23442, 2018 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29805745
15.
A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis.
Transl Oncol
; 11(3): 771-778, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29698934
16.
What's New in SCLC? A Review.
Neoplasia
; 19(10): 842-847, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28888101
17.
RRx-001 protects against cisplatin-induced toxicities.
J Cancer Res Clin Oncol
; 143(9): 1671-1677, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28417195
18.
Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management.
Cancer Chemother Pharmacol
; 80(5): 895-907, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28730291
19.
No patient left behind: The promise of immune priming with epigenetic agents.
Oncoimmunology
; 6(10): e1315486, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29123948
20.
The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury.
Expert Rev Hematol
; 10(6): 575-582, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28448172